A private advisory company has recommended that the agency overseeing Medicare should not reimburse for biomarker tests. This decision has led to significant backlash from cancer specialists who rely on these tests. Biomarker tests play a crucial role in diagnosing and managing cancer. They are vital for personalizing treatment plans and improving patient outcomes.

LeeAnne Loney found herself in a difficult situation in the summer of 2024. The recommendation not to reimburse for these critical tests adds pressure to individuals already navigating challenging health decisions.